Nelson Sun - Feb 14, 2025 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Role
Chief Financial Officer
Signature
/s/ Nelson Sun
Stock symbol
AARD
Transactions as of
Feb 14, 2025
Transactions value $
$160,000
Form type
4
Date filed
2/19/2025, 04:30 PM
Previous filing
Feb 12, 2025
Next filing
Jun 13, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AARD Common Stock Conversion of derivative security +7K +8.49% 89.5K Feb 14, 2025 Direct F1
transaction AARD Common Stock Purchase $160K +10K +11.18% $16.00 99.5K Feb 14, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AARD Series C Convertible Preferred Stock Conversion of derivative security $0 -59.3K -100% $0.00 0 Feb 14, 2025 Common Stock 7K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.